Skip to main content

Retatrutide

Weight Management · 4,731.3 g/mol (C221H342N46O68) · 39 amino acids

Research Chemical - Not for Human Use

Best price per mg

$5.65/mg

with discount code · market North America

3
Vendors
6
Lab tests
100
best rating

Compare Retatrutide prices per mg from 3 vendors, with published certificates of analysis and lab results where available.

Read purity and measured quantity separately: a high purity percentage does not establish the amount in a vial. Match each result to its sample, date and original report.

Description

Retatrutide (LY3437943) is an experimental peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. A receptor receives signals; an agonist activates it. Clinical trials study its effects on body weight and blood sugar. Study results do not verify the quality or effects of supplier products.

Quick Facts

Category
Weight Management
Molecular Weight
4,731.3 g/mol (C221H342N46O68)
Half-Life
~6 days (human phase 1b; Urva et al., 2022)
CAS Number
2381089-83-2
Amino Acids
39
Storage
-20°C lyophilized; 2-8°C reconstituted
Solubility
Soluble in sterile water or bacteriostatic water

A CAS number uniquely identifies a chemical substance.

g/mol describes mass per mole; Da describes the mass of a single molecule. A vendor’s mg value is the mass in the offered package.

Amino acids are the building blocks of a peptide; the count gives their number.

Independent tests of Retatrutide

Bought as a customer, analysed by an independent laboratory.

The score covers its measured scoring axes only. Open the report for unmeasured or non-comparable attributes; it does not establish sterility, safety or efficacy.

  • RC Peptides, 82 passed

    Janoshik Analytical · November 11, 2026

    Reported measurements: LCMS screening, Retatrutide, Purity, Endotoxin, As, Cd, Pb, Hg.

    82passed
  • Avellon Peptides, 92 passed

    Janoshik Analytical · September 11, 2026

    Reported measurements: LCMS screening, As, Cd, Pb, Hg, Endotoxin, Retatrutide, Purity.

    92passed
  • BioLab Shop, 20 not passed

    Janoshik Analytical · September 2, 2026

    Reported measurements: Endotoxin, Retatrutide, Purity, Comment, As, Cd, Pb, Hg.

    20not passed
All tests of Retatrutide

Offers

3 vendorsfrom $5.65/mg with code

CHEMVERIFY −15%
Ad

A Retatrutide certificate of analysis (COA) describes a tested sample. Match the batch identifier, laboratory and methods to the offer. Vendor COAs and tests commissioned by ChemVerify are separate evidence.

Look up a batch COA

Certificates of analysis for Retatrutide

8 vendors publish third-party certificates of analysis for Retatrutide. 49 published reports in total. Best reported purity per vendor: 99.73%–99.89%.

All COA-verified vendors for Retatrutide

Research Summary

Phase 2 obesity and type 2 diabetes trials were published in 2023. Phase 3 TRIUMPH-1 results followed on 29 September 2026. The trials used defined investigational material; they do not establish the identity, quality or effects of supplier products listed here.

Mechanism of Action

Retatrutide activates GIP, GLP-1 and glucagon receptors involved in metabolic signalling. Activating three receptors does not by itself prove superiority over medicines that activate one or two.

Studies and chemical references

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity

Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026) – New England Journal of Medicine

TRIUMPH-1: randomised phase 3 trial in 2,339 adults with obesity without diabetes over 80 weeks. Published 29 September 2026; gastrointestinal events were the most common adverse events.

DOI: 10.1056/nejmoa2604169

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frías JP, et al. (2023) – New England Journal of Medicine

Randomised phase 2 trial in 338 adults: average weight change at 48 weeks was −24.2% in the highest studied group versus −2.1% with placebo. Group averages do not predict individual outcomes.

DOI: 10.1056/nejmoa2301972

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Rosenstock J, Frias J, Jastreboff AM, et al. (2023) – The Lancet

Phase 2 trial in adults with type 2 diabetes examining HbA1c, a measure of average blood sugar, and body weight. Placebo and dulaglutide were comparators.

DOI: 10.1016/s0140-6736(23)01053-x

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. (2022) – Lancet (London, England)

A human phase 1b trial reported an approximate half-life of 6 days. This is a study estimate for the defined investigational molecule, not a measured property of supplier material.

DOI: 10.1016/s0140-6736(22)02033-5

Retatrutide: substance identity and systematic chemical name (NOP2Y096GV)

NCATS; USAN Council nomenclature (2026) – NCATS Global Substance Registration System

The systematic name defines 39 residues with Aib at positions 2 and 20, α-methyl-L-leucine at position 13, Lys17 linked through one AEEA and γ-glutamyl spacer to a C20 diacid, and a C-terminal amide. Aib is α-aminoisobutyric acid. The registry backbone alone omits these modifications and is not the complete molecule.

NCATS Global Substance Registration System

Retatrutide: molecular formula and molar mass (D12430)

KEGG (2026) – KEGG DRUG

C221H342N46O68 gives an average molar mass of 4731.3 g/mol when rounded to one decimal place. This calculated peptide-moiety value excludes counterions and is not a batch measurement.

KEGG DRUG

Studies cited are from published peer-reviewed literature. Referenced for laboratory research context only.

Known Research Compound Interactions

Based on published preclinical research literature

For laboratory research reference only. Not for human consumption. Interaction data derived from preclinical studies and receptor binding profiles. Always consult primary literature for specific research protocols.

Avoid
Caution
Compatible

Interaction assessments based on receptor binding affinity, signaling pathway analysis, and published preclinical data. For laboratory research use only. Not for human consumption.

Molecular Information

Sequence, synonyms, structure

Molecular Weight

4,731.3 g/mol (C221H342N46O68)

Stated Purity

≥98.0%

Half-Life

~6 days (human phase 1b; Urva et al., 2022)

The stated purity is a specification, not a measured result for a particular batch. Check the corresponding analysis report for the measured value.

Amino Acid Sequence

Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Also Known As

LY3437943
Triple G Agonist
GGG Tri-Agonist
mg
mL

For laboratory research use only. Not for human consumption.

For laboratory research use only. Not for human consumption. Must be 18+.